[ad_1] LONDON, November 26, 2020 / PRNewswire / – Haoma Medica today announced the completion of a first human study for NaQuinate, a naphthoquinone carboxylic acid, which is under development as a new orally administered drug for osteoporosis. The first human study launched last year in healthy adults investigated single …
Read More »Haoma Medica completes first human trial for NaQuinate, a new treatment under development for osteoporosis
